Almirall SA : Q3 operating performance a touch better. FY 2023 EBITDA guidance reiterated
>Sales post modest growth but deteriorate sequentially while margins remain soft - Q3 2023 sales reached € 209m (+4% y-o-y vs +8% in Q2 2023, +2% in Q1 2023 and+7% in Q4 2022), a touch above our estimates and aligned with the consensus. As regards its recent product launches, Skilarance maintained the pace seen in Q2 yet was still far from growth territory (-11% vs -11% in Q2 2023 and -22% in Q1 2023), Ilumetri kept up a very strong pace despite facing very hard comp...Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.